Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

Melo, Sônia Aparecida Beato Ximenes de; Kahlert, Christoph; Fernández, Agustín F.; Gammon, Seth T.; Kaye, Judith S.; LeBleu, Valerie S.; Mittendorf, Elizabeth A.; Weitz, Juergen; Rahbari, Nuh N.; Reissfelder, Christoph; Pilarsky, Christian; Fraga, Mario F.; Piwnica‐Worms, David; Kalluri, Raghu

doi:10.1038/s41586-022-05062-9

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing number of studies suggest that various cancerassociated molecules such as oncogenic proteins (HER2, EGFR, FAK, survivin, EMMPRIN, CD24, and EpCAM) and miRNAs are enriched or absent compared with healthy controls [70][71][72][73][74]. In addition, GPC1, FN, and EDIL3 are highly abundant in EVs isolated from the peripheral blood of breast cancer patients compared with healthy individuals [38,52,56,75]. Using a quantitative proteomics approach, Li et al Chena et al, have used a label-free quantitative phosphoproteomics approach and identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer compared with healthy controls [68].…”

Section: Clinical Research and Implications Of Breast Cancer Evmentioning

confidence: 99%

“…A growing number of studies suggest that various cancer‐associated molecules such as oncogenic proteins (HER2, EGFR, FAK, survivin, EMMPRIN, CD24, and EpCAM) and miRNAs are enriched or absent compared with healthy controls [70–74]. In addition, GPC1, FN, and EDIL3 are highly abundant in EVs isolated from the peripheral blood of breast cancer patients compared with healthy individuals [38, 52, 56, 75]. Using a quantitative proteomics approach, Li et al.…”

Section: Ms‐based Analysis Of Ev Proteome In Breast Cancer and Biomar...mentioning

confidence: 99%

See 1 more Smart Citation

Extracellular vesicle proteins as breast cancer biomarkers: Mass spectrometry‐based analysis

Bandu,

Oh,

Kim

2024

Proteomics

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are membrane‐surrounded vesicles released by various cell types into the extracellular microenvironment. Although EVs vary in size, biological function, and components, their importance in cancer progression and the potential use of EV molecular species to serve as novel cancer biomarkers have become increasingly evident. Cancer cells actively release EVs into surrounding tissues, which play vital roles in cancer progression and metastasis, including invasion and immune modulation. EVs released by cancer cells are usually chosen as a gateway in the search for biomarkers for cancer. In this review, we mainly focused on molecular profiling of EV protein constituents from breast cancer, emphasizing mass spectrometry (MS)‐based proteomic approaches. To further investigate the potential use of EVs as a source of breast cancer biomarkers, we have discussed the use of these proteins as predictive marker candidates. Besides, we have also summarized the key characteristics of EVs as potential therapeutic targets in breast cancer and provided significant information on their implications in breast cancer development and progression. Information provided in this review may help understand the recent progress in understanding EV biology and their potential role as new noninvasive biomarkers as well as emerging therapeutic opportunities and associated challenges.

show abstract